Advanced search
1 file | 219.38 KB Add to list

Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis

Author
Organization
Keywords
Azelastine, Allergic rhinitis, Fluticasone, MP29-02, Responder analysis, Severe chronic upper airway disease, FUROATE NASAL SPRAY, QUALITY-OF-LIFE, OCULAR SYMPTOMS, FLUTICASONE PROPIONATE, CONTROLLED-TRIAL, IMPACT, GUIDELINES, MANAGEMENT, BURDEN, IMPLEMENTATION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 219.38 KB

Citation

Please use this url to cite or link to this publication:

MLA
Meltzer, Eli, Paul Ratner, Claus Bachert, et al. “Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.” INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 161.4 (2013): 369–377. Print.
APA
Meltzer, E., Ratner, P., Bachert, C., Carr, W., Berger, W., Canonica, G. W., Hadley, J., et al. (2013). Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 161(4), 369–377.
Chicago author-date
Meltzer, Eli, Paul Ratner, Claus Bachert, Warner Carr, William Berger, G Walter Canonica, James Hadley, et al. 2013. “Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.” International Archives of Allergy and Immunology 161 (4): 369–377.
Chicago author-date (all authors)
Meltzer, Eli, Paul Ratner, Claus Bachert, Warner Carr, William Berger, G Walter Canonica, James Hadley, Phil Lieberman, Frank C Hampel, Joaquim Mullol, Ullrich Munzel, David Price, Glenis Scadding, J Christian Virchow, Ulrich Wahn, Ruth Murray, and Jean Bousquet. 2013. “Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.” International Archives of Allergy and Immunology 161 (4): 369–377.
Vancouver
1.
Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. 2013;161(4):369–77.
IEEE
[1]
E. Meltzer et al., “Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis,” INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 161, no. 4, pp. 369–377, 2013.
@article{4290595,
  author       = {Meltzer, Eli and Ratner, Paul and Bachert, Claus and Carr, Warner and Berger, William and Canonica, G Walter and Hadley, James and Lieberman, Phil and Hampel, Frank C and Mullol, Joaquim and Munzel, Ullrich and Price, David and Scadding, Glenis and Virchow, J Christian and Wahn, Ulrich and Murray, Ruth and Bousquet, Jean},
  issn         = {1018-2438},
  journal      = {INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY},
  keywords     = {Azelastine,Allergic rhinitis,Fluticasone,MP29-02,Responder analysis,Severe chronic upper airway disease,FUROATE NASAL SPRAY,QUALITY-OF-LIFE,OCULAR SYMPTOMS,FLUTICASONE PROPIONATE,CONTROLLED-TRIAL,IMPACT,GUIDELINES,MANAGEMENT,BURDEN,IMPLEMENTATION},
  language     = {eng},
  number       = {4},
  pages        = {369--377},
  title        = {Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis},
  url          = {http://dx.doi.org/10.1159/000351404},
  volume       = {161},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: